A federal court has denied Sagebrush Health Services' request to intervene in a legal dispute involving drug discount certifications under the 340B program. The ruling affects Sagebrush and its affiliated clinics, which rely on the program to obtain discounted medications for patients. The decision highlights the importance of timely intervention in legal proceedings and the implications for healthcare organizations involved in the 340B program.

The case, Genentech, Inc. v. Fink, was decided by Chief Judge James E. Boasberg in the District Court for the District of Columbia. The court ruled that Sagebrush's motions to intervene were untimely and denied them based on procedural grounds. This ruling comes after a judgment was made in favor of pharmaceutical companies challenging the Health Resources and Services Administration's (HRSA) certification of Sagebrush's affiliate sites.

Background

The dispute centers around the 340B Drug Pricing Program, which allows certain healthcare providers, known as “covered entities,” to purchase medications at reduced prices. Sagebrush Health Services, a non-profit organization, has been identified as a prolific participant in this program. However, the pharmaceutical companies involved in the case, including Genentech, Amgen, Eli Lilly, and UCB, argued that Sagebrush's affiliates were not eligible for certification under the program.

In December 2024 and January 2025, the pharmaceutical companies filed lawsuits against the government, challenging the certification of nine of Sagebrush's affiliates as covered entities. They claimed that these affiliates did not meet the statutory requirements to receive 340B discounts. Sagebrush was aware of the arguments being made in these lawsuits but chose not to intervene until after the court had issued a final judgment in favor of the pharmaceutical companies.

The Ruling

The court ruled that Sagebrush's motions to intervene were untimely, stating, "Litigation is not a spectator sport. If an interested party wishes to call the plays, the Federal Rules of Civil Procedure require him to seek intervention in a timely manner." The judge emphasized that Sagebrush had ample opportunity to intervene before the court's final judgment but failed to do so.

Chief Judge Boasberg noted that Sagebrush's request to intervene came 28 days after the court's ruling, which was too late. He stated, "Sagebrush did not seek to intervene as soon as it became clear that the Government was not (allegedly) adequately representing its interests." The court's decision effectively denied Sagebrush the opportunity to challenge the ruling that set aside the certifications of its affiliate clinics.

Impact

This ruling has significant implications for Sagebrush and its affiliates, as it prevents them from participating in the legal proceedings that could affect their eligibility for the 340B program. The court's decision reinforces the necessity for interested parties to act promptly in legal disputes to protect their rights. It also underscores the challenges faced by healthcare organizations in navigating complex regulatory environments.

The ruling may set a precedent for future cases involving intervention in administrative disputes, particularly in the context of healthcare and pharmaceutical regulations. Organizations that believe their interests may be affected by ongoing litigation must be vigilant and proactive in seeking intervention to avoid being sidelined.

What's Next

Sagebrush's options for appeal remain unclear, as the court's ruling was based on procedural grounds. The Government has also filed an appeal in the case, which could lead to further developments in the litigation. Details were not available in the court filing regarding any related cases pending.